Phosphatidylinositol 3-kinase and protein kinase C are required for the inhibition of caspase activity by epidermal growth factor  by Lan, Li & Wong, Nai-Sum
Phosphatidylinositol 3-kinase and protein kinase C are required for the
inhibition of caspase activity by epidermal growth factor
Li Lan, Nai-Sum Wong*
Department of Biochemistry, Faculty of Medicine, University of Hong Kong, Hong Kong, PR China
Received 22 December 1998
Abstract The mechanism by which growth factors exert an
anti-apoptotic function on many cell types is not well understood.
This issue is addressed in relation to epidermal growth factor
(EGF) which inhibits apoptosis induced by staurosporine or
wortmannin in an epithelial tumour cell line (CNE-2). The
presence of EGF substantially reduced the in vitro Ac-DEVD-
AMC hydrolytic activity and almost completely suppressed the
intracellular cleavage of poly(ADP-ribose) polymerase in
staurosporine- or wortmannin-treated cells. Staurosporine but
not wortmannin caused the intracellular proteolytic processing of
pro-caspase-3 and this event was transiently inhibited by EGF.
Staurosporine-induced apoptosis was not inhibited by EGF in the
presence of wortmannin or LY294002. Similarly, EGF failed to
inhibit wortmannin-induced apoptosis in the presence of staur-
osporine, chelerythrine chloride or Goº6850. These results suggest
that phosphatidylinositol 3-kinase and protein kinase C play a
role in the survival function of EGF but the reduction of cellular
caspase activity cannot be satisfactorily explained by a lack of
pro-caspase-3 activation.
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1. Introduction
Apoptosis is the process by which cells are eliminated from
a tissue without eliciting an in£ammatory response. Apoptosis
can be mechanistically divided into two phases: a regulatory
and an execution phase [1]. In the regulatory phase, cells
receive signals from the extracellular or intracellular environ-
ment and through a network of interacting intracellular sig-
nalling pathways produce either positive (activating) or neg-
ative (inhibitory) regulation of the execution phase. This latter
phase is now thought to be responsible for the irreversible
stage of apoptosis as characterised by the internucleosomal
cleavage of chromosomal DNA [1^3]. The activation of the
execution phase involves the activation of proteases known as
caspases (cysteinyl aspartate-speci¢c proteinases) which are
synthesised as inactive proenzymes [3,4]. Caspases have a gen-
eral structure consisting of three domains: the NH2-terminal
prodomain, the large and the small subunits. During activa-
tion, proteolytic cleavage occurs between the domains, at sites
that are preceded by an aspartic acid residue. The prodomain
is discarded and the large and small subunits associate togeth-
er to form the active enzyme [5]. Overexpression of caspases in
cells has previously been shown to induce apoptosis [6]. The
substrates for the mammalian caspases include poly(ADP-ri-
bose) polymerase (PARP), the lamins, the retinoblastoma pro-
tein, the sterol regulatory element binding protein and L-actin,
which are degraded at the onset of apoptosis [7^11]. One
important target of these caspases is DNA fragmentation fac-
tor (DFF). Proteolytic cleavage of DFF releases an active
endonuclease that degrades DNA at internucleosomal sites
[2].
Apoptosis can be prevented in many instances by growth
factors such as insulin-like growth factor, nerve growth factor
and granulocyte macrophage colony stimulating factor [12^
14]. Although it is highly likely that those growth factors
act via the regulatory phase of apoptosis, little is known about
the underlying molecular mechanism. There is increasing evi-
dence that phosphatidylinositol 3-kinase (PI 3-kinase) is
widely involved in the survival functions of many growth
factors [12,13]. Many studies now tend to support a model
whereby PI 3-kinase activates an intracellular serine kinase,
AKT/PKB, which probably acts through inhibition of the
activation of the caspases [15,16]. Recent studies have also
documented the involvement of protein kinase C (PKC) iso-
forms, such as PKCK and the atypical PKCs, in cellular sur-
vival [17,18]. Previously, epidermal growth factor (EGF) was
shown to be able to suppress apoptosis in a number of cell
lines of epithelial origin [19^21]. The survival function of EGF
is correlated to the expression of Bcl-xL which is one of the
pro-survival protein of the Bcl-2 family [20,21]. Bcl-xL is able
to bind Apaf1, and hence prevents the formation of a super-
molecular complex that is essential for the activation of cas-
pase-9 [22]. It is therefore possible that EGF, through the
mediation of Bcl-xL, negatively regulates the caspase activity
within cells, and hence acts as a survival factor. To test this
hypothesis, the ¢rst step would be to see if EGF treatment of
cells resulted in the reduction of caspase activities. We found
that EGF could inhibit apoptosis induced by staurosporine or
wortmannin in an epithelial tumour cell line and it caused a
reduction of caspase activity as well as the intracellular cleav-
age of PARP. But such reduction in caspase activity is not
completely due to a lack of activation of pro-caspase-3. The
EGF-stimulated inhibition of caspase activity is inhibited by
inhibitors of PI 3-kinase and PKC, suggesting the involvement
of these two signalling proteins in this process.
2. Materials and methods
2.1. Materials
EGF, RPMI 1640 medium, foetal calf serum (FCS), penicillin and
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streptomycin were purchased from Gibco BRL (Life Technologies
Inc., New York). Ac-DEVD-AMC (N-acetyl-Asp-Glu-Val-Asp-7-ami-
no-4-methylcoumarin) and LY294002 were from BioMol Research
Laboratories (Plymouth Meeting, PA). Chelerythrine chloride and
Goº6850 were from Calbiochem (La Jolla, CA). Acridine orange,
staurosporine, wortmannin and the bicinchoninic acid (BCA) assay
kit were from Sigma Chemical (St. Louis, MO). Mouse anti-human
caspase-3 antibody, horseradish peroxidase (HRP)-conjugated anti-
mouse IgG or anti-rabbit IgG antibody and enhanced chemilumines-
cence (ECL) kit were from Transduction Laboratories, (Lexington,
KY). Rabbit anti-human PARP polyclonal antibody was from Up-
state Biotechnology (Lake Placid, NY).
2.2. Culture of CNE-2 cells
The CNE-2 cell line is an epithelial tumour cell line originally iso-
lated and established from a patient with poorly di¡erentiated naso-
pharyngeal carcinoma [23] and was kindly provided by Professor
W.F. Fong of the City University of Hong Kong. The CNE-2 cells
grown as a monolayer were maintained in RPMI 1640 medium sup-
plemented with 5% FCS, 100 U/ml penicillin, 100 Wg/ml streptomycin
under a humidi¢ed atmosphere of 5% CO2/95% O2 in a 37‡C incu-
bator. Prior to experiments, cells were grown to 90% con£uence and
were quiesced by incubation in serum-free RPMI 1640 medium for
12 h.
2.3. Analysis of apoptosis by transmission electron microscope
After treatment with staurosporine for 6 h, cells were scraped from
the culture dishes and pelleted by centrifugation. The cell pellets were
washed once with ice-cold phosphate bu¡ered saline (PBS, pH 7.4).
The cells were ¢xed in 0.1 M sodium cacodylate bu¡er containing
2.5% glutaraldehyde. Ultrathin sections were stained with uranyl ace-
tate and lead citrate as described before [24]. The sections were exam-
ined in a Jeol JEM 2000FX transmission electron microscope.
2.4. Quanti¢cation of apoptosis by the method of acridine orange
staining
Identi¢cation of apoptotic cells by acridine orange staining was
done essentially as described previously [25]. After treatment of cells
with the appropriate stimuli for a certain period of time, cells were
trypsinised and collected, followed by washing once with ice-cold
PBS. After cells were resuspended and ¢xed in PBS containing 1%
formaldehyde, the cells were stained with acridine orange (100 Wg/ml
in deionised H2O) and then examined under a £uorescence micro-
scope. Apoptotic cells were identi¢ed as those containing densely £uo-
rescing bodies due to nuclear fragmentation and chromatin conden-
sation. At least 500 cells from each sample were counted and the
percentage of apoptotic cells was taken as the extent of apoptosis.
Each quanti¢cation was done in triplicate.
2.5. Identi¢cation of internucleosomal DNA cleavage in apoptotic cells
The internucleosomal cleavage of DNA was analysed as described
[24]. Following treatment with the appropriate stimuli, the cells were
rinsed with ice-cold PBS and harvested by trypsinisation. The cell
pellets were resuspended and incubated in 10 mM Tris-HCl (pH
7.4) containing 25 mM EDTA, 0.5% SDS and 0.1 mg/ml proteinases
K at 50‡C overnight. The digested cells were extracted for DNA with
phenol/chloroform/isoamyl alcohol (25:24:1). The extracted DNA
was precipitated and digested in 10 mM Tris (pH 8.0) containing
1 mM EDTA and 10 Wg/ml RNase for 1 h at 37‡C. 10 Wg of DNA
per sample was separated by electrophoresis in a 1.8% agarose gel
impregnated with ethidium bromide (0.5 Wg/ml). The DNA pattern
was examined by ultraviolet transillumination.
2.6. Measurement of sub-G1 DNA content by £ow cytometry
CNE-2 cells were treated with an apoptotic stimulus for 24 h. The
incubation medium was removed and cells were trypsinised, washed
with ice-cold PBS and ¢xed in ice-cold 70% ethanol for at least 30 min
on ice. The ¢xed cells were stored at 320‡C until analysis. Prior to
analysis, the cells were rinsed twice with PBS, and stained with a
propidium iodide solution (40 Wg/ml with 0.1 mg/ml RNase in PBS)
at 37‡C for 30 min. Analysis was performed by a £uorescence acti-
vated cell sorter (Coulter EPICS XL, UK) as described [26]. The
percentage of cells in the G0/G1, S and G2/M phases of the cell cycle
was calculated from the resultant DNA histogram using Multicycle
AV software (Phoenix Flow System, San Diego, CA). Cells in the sub-
G1 peak of the DNA histogram represent those containing a subdi-
ploid amount of DNA and are regarded as apoptotic.
2.7. Detection of caspase-3 and PARP cleavage by Western blotting
The cleavage of caspase-3 and PARP in apoptotic cells was moni-
tored by Western blot analyses essentially as previously described [27].
Cells were ¢rst treated with an apoptotic stimulus for various time
intervals. At the end of each time interval, the cells were rinsed once
with ice-cold PBS and then lysed in 20 mM Tris pH 7.5, 50 mM NaF,
20 mM NaCl, 1 mM EDTA, 2 mM DTT, 0.2 mM PMSF, and 0.5%
NP-40 on ice for 20 min. The cells were scraped from the dishes and
passed several times through a 26-gauge needle to disperse any large
aggregations. After centrifugation at 13 000 rpm at 4‡C for 10 min, 50
Wg of the cell lysate was separated by electrophoresis under reducing
conditions in either a 10% or 12% SDS-polyacrylamide gel. An iden-
tical amount of proteins from a Jurkat cell or HeLa cell lysate was
run in parallel with the samples to serve as a positive control for the
32 kDa pro-caspase-3 and 116 kDa PARP respectively. After transfer
of proteins to nitrocellulose membrane, the membrane was blocked
with TBS (10 mM Tris pH 7.6, 100 mM NaCl) containing 0.01%
Tween 20 and 5% (w/v) skim milk powder to block non-speci¢c bind-
ing. To detect pro-caspase-3, the membrane was ¢rst incubated with a
mouse anti-human caspase-3 antibody. A HRP-conjugated anti-
mouse IgG antibody was used as the second antibody to enable de-
tection of pro-caspase-3 by the ECL method. To detect PARP by the
same method, a rabbit anti-human PARP polyclonal antibody was
used as the ¢rst antibody, and a HRP-conjugated anti-rabbit IgG
antibody was used as the second antibody.
2.8. Fluorimetric assay of caspase activity
After treatment with the appropriate stimuli, the cells were washed
once with ice-cold PBS and lysed in a lysis bu¡er containing 20 mM
Tris-HCl (pH 7.5), 5 mM DTT, 2 mM EDTA and 0.1% CHAPS. The
amount of protein was determined for each lysate using the BCA
protein assay kit. 15^20 Wl of each of the cell lysates, which had the
same protein concentrations, was incubated in a ¢nal volume of 100
Wl of a reaction bu¡er containing 50 mM Tris-HCl pH 7.5, 2 mM
DTT, 10% glycerol and 100 WM Ac-DEVD-AMC for 30 min at 30‡C.
Caspase activity was determined with Ac-DEVD-AMC as a speci¢c
substrate by liberation of AMC from Ac-DEVD-AMC as described
previously [28]. Fluorescence intensity was quanti¢ed using the Hita-
chi 650-60 spectrophotometer at excitation and emission wavelengths
of 380 and 460 nm respectively. Enzyme activity is expressed as £uo-
rescent units per mg of protein per min.
2.9. Statistical analysis
Where appropriate, data are mean values of three independent ex-
periments and are expressed as mean þ S.D. Student’s t-test was used
to compare data. A P value of less than 0.05 is regarded as signi¢cant.
3. Results
3.1. EGF promotes the survival of the CNE-2 cells
Initial experiments demonstrated that staurosporine or
wortmannin dose-dependently and reproducibly induced
apoptosis in CNE-2 cells at or above 20 nM and 4 WM re-
spectively. Examination of the staurosporine-treated cells by
electron microscopy revealed cytoplasmic compaction with no
structures that was distinctly reminiscent of the nuclei. High-
density intracellular bodies due to condensation of chromatin
were formed in the drug-treated cells. By contrast, the control
cells still retained a well-de¢ned nucleus with no evidence of
chromatin condensation (Fig. 1A). The genomic DNA was
extracted from drug-treated or control cells and fractionated
by agarose electrophoresis. Fig. 1B showed that in both the
staurosporine- and wortmannin-treated cells but not in the
control cells, fragmentation of DNA characteristic of apopto-
sis was observed. Analysis of DNA content by £ow cytometry
revealed a much higher proportion of cells with sub-G1 DNA
content upon treatment with either drugs (Fig. 1C). Thus in
the control cells, only 2.2% of the cells had sub-G1 DNA but
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this value increased to 19.3% and 35.5% for the staurosporine-
and wortmannin-treated cells respectively. The apoptotic cells
could easily be distinguished from the normal cells by staining
with acridine orange. Upon treatment with either drug, many
cells shrank considerably due to cytoplasmic condensation,
with the formation of densely £uorescing bodies which might
be a result of chromosomal condensation and fragmentation
(Fig. 1D).
To see if EGF would counteract the apoptotic e¡ect of
staurosporine and wortmannin, CNE-2 cells were incubated
in the presence of EGF for 15 min prior to treatment with
either staurosporine or wortmannin for 12 h. The cells were
harvested and stained with acridine orange and the percentage
of cells displaying typical features of apoptosis was deter-
mined. Signi¢cant reduction of staurosporine- and wortman-
nin-induced apoptosis could already be seen in cells pre-
treated with 10 ng/ml EGF. At an EGF dosage of 100 ng/
ml, the percentage of cells with apoptotic features decreased
by approximately 50% and 60% upon staurosporine and wort-
mannin treatment respectively (Fig. 2).
3.2. The e¡ect of EGF on the activity of caspase
The enzyme activity of caspase was then measured in cells
treated with staurosporine or wortmannin to see if the reduc-
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Fig. 1. Induction of apoptosis in CNE-2 cells. A: The ultrastructural morphology of cells examined by electron microscopy after treatment
with or without staurosporine (1 WM) for 6 h. Magni¢cation U1500. B: Examination of internucleosomal cleavage of DNA by agarose gel
electrophoresis in cells receiving either no treatment, or treatment with 50 nM staurosporine or 4 WM wortmannin for 12 h. C: The cells were
treated with either staurosporine (20 nM) or wortmannin (4 WM) for 24 h. The cells were harvested, ¢xed and stained with propidium iodide.
The stained cells were analyzed for DNA content by £ow cytometry. D: After treatment with either staurosporine (50 nM) or wortmannin
(4 WM) for 12 h, the cells were harvested, ¢xed and stained with acridine orange. The stained cells were examined by £uorescence microscopy.
Magni¢cation U400. C: control; STS: staurosporine; Wort: wortmannin.
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tion of apoptosis was associated with a similar reduction of
caspase activity. Cells were treated with either 50 nM staur-
osporine or 4 WM wortmannin alone or in the presence of 100
ng/ml EGF for 12 h. The caspase activity was then measured
in the cell lysates using Ac-DEVD-AMC as a substrate. The
caspase activity in cells treated with both staurosporine and
EGF was only 50% of that found in cells treated with staur-
osporine alone. A similar percentage of reduction of caspase
activity was seen in cells treated with both wortmannin and
EGF, in comparison to cells treated with wortmannin only
(Fig. 3).
The e¡ect of diminished caspase enzyme activity on the
intracellular degradation of PARP, which is one of the com-
monest proteins found to be cleaved during apoptosis, was
then examined by monitoring the time course of proteolytic
cleavage of PARP. In cells treated with staurosporine alone
for 6 h, Western analysis showed that the 116 kDa PARP was
cleaved to produce the 85 kDa fragment which continued to
accumulate over the next 6 h. By the end of the 24 h incuba-
tion period, almost all the 116 kDa PARP was converted to
the 85 kDa form (Fig. 4A). In the presence of both EGF and
staurosporine, there was very little cleavage of the 116 kDa
PARP to form the 85 kDa fragment after 6 and even up to
12 h of incubation. In cells treated with wortmannin alone, a
decrease in the 116 kDa form of PARP and a simultaneous
appearance of an 85 kDa fragment of PARP were detected
after 6 h of incubation. Unlike staurosporine, there was no
further accumulation of the 85 kDa PARP fragment over the
rest of the 24 h incubation period. The abundance of the 85
kDa form of PARP was substantially reduced in the presence
of both EGF and wortmannin (Fig. 4B).
The cleavage of PARP, which is a substrate for caspase-3 in
the apoptotic cells, suggests that this caspase might be acti-
vated in these cells. The activation of pro-caspase-3 can be
monitored by following its proteolytic cleavage which is man-
ifested as the disappearance of the 32 kDa form [27,29]. The
time course of change in the 32 kDa form of this caspase was
therefore monitored by Western analysis. After 6 h of treat-
ment, the protein level of the 32 kDa pro-caspase-3 decreased
markedly in cells treated with staurosporine alone while most
of the 32 kDa pro-caspase-3 still remained in the EGF/staur-
osporine-treated cells. However, this inhibition of pro-cas-
pase-3 processing was only transient since after 12 h of incu-
bation, almost all of the 32 kDa caspase had also disappeared
in the EGF/staurosporine-treated cells, to the same extent as
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Fig. 4. The cleavage of PARP and pro-caspase-3 in the absence or presence of EGF. Cells were treated with 50 nM staurosporine or 4 WM
wortmannin alone, or in the presence of 100 ng/ml EGF for various time intervals as indicated. At the end of incubation, the cell lysate was
analysed for the proteolytic cleavage by Western blotting. A and B: Cleavage of PARP in staurosporine- or wortmannin-treated cells and its
inhibition by EGF. C and D: Cleavage of pro-caspase-3 in the absence or presence of EGF. A and C: lane 1: zero time control; lanes 2^5:
cells treated with staurosporine for 3, 6, 12, 24 h respectively; lanes 6 and 7: cells treated with EGF and staurosporine for 6 and 12 h respec-
tively; lane 8: cells treated with EGF for 12 h. B and D: lane 1: zero time control; lanes 2^4: cells treated with wortmannin for 6, 12, 24 h re-
spectively; lanes 5^7: cells treated with EGF and wortmannin for 6, 12, 24 h respectively.
Fig. 3. The e¡ect of EGF on the enzyme activity of caspase(s). Cells
were treated with 50 nM staurosporine or 4 WM wortmannin in the
absence or presence of 100 ng/ml EGF for 12 h. The enzyme activ-
ity of caspases in the cell lysate was assayed with Ac-DEVD-AMC
as a substrate. The values are expressed as mean þ S.D. from three
di¡erent experiments. STS: staurosporine; EGF: epidermal growth
factor; Wort: wortmannin.
Fig. 2. Anti-apoptotic e¡ects of EGF in CNE-2 cells. Cells were in-
cubated with EGF at 0, 1, 10 or 100 ng/ml for 15 min followed by
addition of 50 nM staurosporine or 4 WM wortmannin for 12 h.
The cells were stained with acridine orange and the apoptotic cells
were identi¢ed and counted as explained in Section 2. The reduction
of apoptosis was calculated as a percentage of the control, i.e. cells
treated with staurosporine or wortmannin only. The percentages are
expressed as mean þ S.D. from three independent experiments.
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in cells treated with staurosporine alone (Fig. 4C). Rather
unexpectedly, the protein level of the 32 kDa pro-caspase-3
in cells treated with wortmannin alone or with wortmannin
and EGF together did not decrease signi¢cantly throughout
the entire incubation period, suggesting that the proteolytic
processing of pro-caspase-3 did not occur in wortmannin-in-
duced apoptosis (Fig. 4D).
3.3. E¡ects of PI 3-kinase inhibitors on the ability of EGF to
prevent staurosporine-induced apoptosis
To identify the intracellular signalling molecules that might
mediate the survival e¡ect of EGF on apoptosis, we ¢rst in-
vestigated the e¡ect of speci¢c inhibitors of PI 3-kinase on
EGF’s ability to inhibit apoptosis induced by staurosporine.
We used a relatively low concentration (100 nM) of wortman-
nin, which has been shown to fully inhibit the activity of PI 3-
kinase in a wide variety of cell types [13,30]. The reduction of
staurosporine-induced apoptosis by EGF in the absence and
presence of PI 3-kinase inhibitors was measured by the acri-
dine orange assay (Fig. 5A) as well as cleavage of PARP (Fig.
5B). Wortmannin at 100 nM did not induce apoptotic mor-
phological changes and cleavage of PARP in CNE-2 cells. As
expected, staurosporine induced a signi¢cant percentage of
cells with apoptotic morphology and cleavage of PARP and
this was inhibited by EGF. However, this survival e¡ect of
EGF was not seen in the presence of wortmannin. The per-
centage of apoptosis and the cleavage of PARP were approx-
imately the same as in cells treated with staurosporine alone.
Another speci¢c PI 3-kinase inhibitor, LY294002 [31], at 5 WM
has the same e¡ect of wortmannin to inhibit the survival
action of EGF. LY294002 by itself also did not induce any
apoptosis and cleavage of PARP.
3.4. E¡ects of PKC inhibitors on the ability of EGF to prevent
wortmannin-induced apoptosis
The involvement of PKC in the survival action of EGF was
also investigated in cells induced to undergo apoptosis by
wortmannin. The reduction of wortmannin-induced apoptosis
by EGF in the absence or presence of PKC inhibitors was
again measured by the acridine orange assay (Fig. 6A) and
also by monitoring of PARP cleavage (Fig. 6B). On its own,
wortmannin induced a substantial percentage of cells with
apoptotic morphology and cleavage of PARP to form the
85 kDa fragment. However, in the presence of EGF, the per-
centage of cells with apoptotic morphology and the cleavage
of PARP were markedly reduced. This e¡ect of EGF was
mimicked by the PKC activator TPA. To see if inhibition of
PKC would abolish the survival e¡ect of EGF, we ¢rst used a
low concentration of staurosporine (10 nM) on its own so that
no apoptosis was induced. In the presence of staurosporine
(10 nM) and EGF, the percentage of wortmannin-induced
apoptosis and cleavage of PARP was not reduced when com-
pared to cells treated with wortmannin alone. To con¢rm this
result, two other PKC inhibitors, chelerythrine chloride [32]
and Goº6850 [33], were used. When either of these inhibitors
was added together with EGF during treatment of cells with
wortmannin, the percentage of apoptosis resulting was statis-
tically indistinguishable from that obtained with wortmannin
alone. Consistently, the cleavage of PARP was not prevented
by EGF in the presence of chelerythrine chloride.
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Fig. 6. Role of PKC in the anti-apoptotic function of EGF. To ex-
amine the e¡ect of PKC inhibition, cells were treated with 10 nM
staurosporine or 2 WM chelerythrine chloride or 100 nM Goº6850
for 15 min, cells were incubated with 100 ng/ml EGF and 4 WM
wortmannin for 12 h. To examine the e¡ect of PKC activation, cells
were incubated with 100 nM TPA alone or in combination with
4 WM wortmannin for 12 h. The percentage of apoptosis was deter-
mined by acridine orange staining (A) and the cleavage of PARP
was determined by Western blot analysis (B). B: lane 1: untreated
cells ; lane 2: 4 WM wortmannin; lane 3: EGF+4 WM wortmannin;
lane 4: TPA+4 WM wortmannin; lane 5: 10 nM staurospori-
ne+EGF+4 WM wortmannin; lane 6: 2 WM chelerythrine chlori-
de+EGF+4 WM wortmannin; lane 7: 10 nM staurosporine; lane 8:
2 WM chelerythrine chloride; lane 9: 100 nM TPA.
Fig. 5. E¡ects of PI 3-kinase inhibitors on the survival action of
EGF. After treatment with 100 nM wortmannin or 5 WM
LY294002, cells were incubated with 100 ng/ml EGF and 50 nM
staurosporine for 12 h. The percentage of apoptosis was determined
by acridine orange staining (A) and the cleavage of PARP was de-
termined by Western blot analysis (B). B: lane 1: untreated cells ;
lane 2: 50 nM staurosporine; lane 3: EGF+50 nM staurosporine;
lane 4: 100 nM wortmannin+EGF +50 nM staurosporine; lane 5:
5 WM LY294002+EGF+50 nM staurosporine; lane 6: 100 nM wort-
mannin; lane 7: 5 WM LY294002.
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4. Discussion
Previous studies have demonstrated that EGF protected
cells against apoptosis under certain circumstances [19^21].
The details of the underlying mechanism are not known but
the pro-survival protein Bcl-xL is suggested to be involved
[20,21]. We made use of CNE-2 cells which could be induced
to undergo apoptosis by either staurosporine or wortmannin
to address the possibility that the survival action of EGF
requires the inhibition of caspase activity. The survival action
of EGF on the CNE-2 cells was demonstrated by its ability to
substantially reduce the percentage of cells with apoptotic
features upon treatment with either of the two drugs (Fig.
2). The hydrolytic activity towards the caspase-speci¢c sub-
strate Ac-DEVD-AMC was also substantially reduced in cell
lysates prepared from cells treated with either staurosporine
or wortmannin, and EGF. This provides the ¢rst experimental
evidence that caspase(s) could serve as a target for the survival
action of EGF. This conclusion was supported by the result
that when cells are treated with both EGF and staurosporine
or wortmannin, the cleavage of PARP to form the 85 kDa
fragment was severely inhibited (Fig. 4A).
Since PARP is a speci¢c substrate for caspase-3 [7,34], the
possibility that this caspase is a target for EGF is investigated.
We therefore performed experiments to monitor the activation
of pro-caspase-3 by following its cleavage during incubation
with staurosporine or wortmannin alone or in the presence of
EGF. These experiments gave rise to two novel observations.
First, in cells treated with staurosporine and EGF together,
the proteolytic processing of pro-caspase-3 was only transi-
ently inhibited, resulting in a delay of that event for approx-
imately 6 h so that complete proteolytic processing of pro-
caspase-3 could only be seen after 12 h of incubation. How-
ever, even when almost all the pro-caspase-3 had undergone
proteolytic processing and should become active, most of the
PARP still remained in the uncleaved state (Fig. 4A,C) and
the measured in vitro Ac-DEVD-AMC activity was only half
of that seen in staurosporine-treated cells (Fig. 3). This result
therefore suggests that the lack of PARP cleavage and the
reduction of in vitro Ac-DEVD-AMC hydrolytic activity
could not be accounted for simply by a lack of activation of
pro-caspase-3 in these cells. Further experiments will be re-
quired to identify the mechanism that is responsible for the
inhibition of the caspase activity, for example, by measuring
the expression and activity of IAP, which could inhibit cas-
pases activity [35]. Second, the proteolytic processing of pro-
caspase-3 is undetectable for apoptosis stimulated by wort-
mannin, and the cleavage of PARP to form the 85 kDa
form occurs to a much lesser extent than for the staurospor-
ine-treated cells. This is the ¢rst indication that staurosporine
and wortmannin induced apoptosis through di¡erent mecha-
nisms in the same cells.
The stimulation of the EGF receptor is known to activate a
number of signalling pathways, including the activation of
breakdown of phospholipids, the activation of the MAP ki-
nase cascade, and the mobilisation of calcium [36]. Two of
these signalling pathways, the activation of PI 3-kinase and
PKC, were shown in many other systems to have survival-
promoting functions [12^14,17,18]. To see if these pathways
were involved in the survival function of EGF, we used spe-
ci¢c inhibitors to inhibit the activity of these kinases. Wort-
mannin at a concentration which is known to achieve full
suppression of PI 3-kinase in most cell types [13,30] was
able to abolish the ability of EGF to protect cells against
staurosporine-induced apoptosis. Another inhibitor of PI 3-
kinase, LY294002, was also able to inhibit the same action of
EGF, providing convincing evidence that PI 3-kinase, which is
known to be activated by the EGF receptor, serves in the anti-
apoptosis signalling pathway of EGF. Since EGF is also ca-
pable of protecting cells against wortmannin-induced apopto-
sis, another pathway not involving PI 3-kinase must exist to
mediate the protective action of EGF. The presence of staur-
osporine and two other PKC inhibitors, chelerythrine chloride
and Goº6850, could totally abolish the anti-apoptotic action of
EGF, suggesting that a PKC-mediated pathway is triggered
by the activated EGF receptor to inhibit apoptosis. This is
mirrored by the ¢nding that TPA, which can activate PKC,
was able to mimic the ability of EGF for inhibiting wortman-
nin-induced apoptosis.
In summary, our experiments demonstrate that the survival
action of EGF is associated with a reduction of caspase ac-
tivity but this cannot be explained entirely on the basis of
inhibition of caspase-3 activation, which after all occurred
only transiently. The inhibition of caspase activity seen in
the presence of activation of pro-caspase-3 suggests that other
mechanism(s), apart from delaying of pro-caspase-3 activa-
tion, is employed by EGF to inhibit apoptosis. Although
staurosporine and wortmannin could induce apoptosis in the
same cells, they may trigger two apoptotic pathways that may
di¡er in the requirement for pro-caspase-3 activation. These
two pathways could be respectively inhibited by a PI 3-kinase
and a PKC-dependent mechanism, both of which are acti-
vated in the CNE-2 cells by EGF stimulation.
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